Yao Zhengbin 4
4 · ArriVent BioPharma, Inc. · Filed Feb 14, 2025
Insider Transaction Report
Form 4
Yao Zhengbin
DirectorPresident and CEO
Transactions
- Award
Stock Option (right to buy)
2025-02-03+380,000→ 380,000 totalExercise: $27.56Exp: 2035-02-03→ Common Stock (380,000 underlying)
Footnotes (1)
- [F1]The shares underlying this option vest as to 25% on February 3, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.